SCHEMBL20006619

SCHEMBL20006619

N#Cc1ccc2c(c1)CCC1C2CCC23CC2=CCC13

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.56
ESR1 P03372 8/20 0.46
STS P08842 3/20 0.44
ESR2 Q92731 7/20 0.43
ABCB11 O95342 2/20 0.43
HSD17B1 P14061 4/20 0.42
HSD17B10 Q99714 4/20 0.41
LMNA P02545 3/20 0.41
SHBG P04278 3/20 0.41
AKR1B10 O60218 2/20 0.41
CYP1A2 P05177 2/20 0.41
PGR P06401 2/20 0.41
SERPINA6 P08185 2/20 0.41
CYP3A4 P08684 2/20 0.41
AR P10275 2/20 0.41
MAPT P10636 2/20 0.41
AKR1B1 P15121 2/20 0.41
SLC6A4 P31645 2/20 0.41
SNCA P37840 2/20 0.41
HTR2B P41595 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20006549 0.77 AKR1C3 (0.67) AKR1C3ESR1STSESR2HSD17B1
SCHEMBL13951936 0.77 STS (0.71) ESR1STSESR2HSD17B1HSD17B10
SCHEMBL15973296 0.77 STS (0.71) ESR1STSESR2HSD17B1HSD17B10
SCHEMBL14048667 0.76 HSD17B10 (0.73) ESR1STSESR2ABCB11HSD17B10
SCHEMBL17525944 0.75 SHBG (0.70) AKR1C3ESR1STSESR2ABCB11
SCHEMBL15974295 0.75 CYP17A1 (0.60) AKR1C3ESR1
SCHEMBL20006567 0.75 CYP17A1 (0.60) AKR1C3ESR1
SCHEMBL15973298 0.74 AKR1C3 (0.53) AKR1C3ESR1STSESR2ABCB11
SCHEMBL14048666 0.74 LMNA (0.56) AKR1C3ESR1STSESR2ABCB11
SCHEMBL20006198 0.72 AKR1C3 (0.65) AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2958928-B1 ESTRA-1,3,5(10),16-TETRAENE-3-CARBOXAMIDES FOR INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE (AKR1 C3) Bayer Pharma AG (DE) 2018-03-28 EP disclosed